For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JVH865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 24, 2025.
Charting a New Path to Better Outcomes With TROP2-Targeting ADCs in Lung Cancer: Unveiling Potential, Shaping Tomorrow
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Disclosure information is available at the beginning of the video presentation.
View all episodes
By PVI, PeerView Institute for Medical Education
4.3
99 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JVH865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 24, 2025.
Charting a New Path to Better Outcomes With TROP2-Targeting ADCs in Lung Cancer: Unveiling Potential, Shaping Tomorrow
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Disclosure information is available at the beginning of the video presentation.
129 Listeners
6 Listeners
31 Listeners
3 Listeners
3 Listeners
10 Listeners
5 Listeners
28 Listeners
9 Listeners
3 Listeners
2 Listeners
5 Listeners
3 Listeners
3 Listeners
5 Listeners
5 Listeners
2 Listeners
0 Listeners
9 Listeners
317 Listeners
42 Listeners
2 Listeners
110 Listeners
2 Listeners
480 Listeners
54 Listeners
43 Listeners
21 Listeners
321 Listeners
54 Listeners
9 Listeners
166 Listeners
36 Listeners